Echo completes topical analgesic device clinical
This article was originally published in The Tan Sheet
Executive SummaryEcho Therapeutics completes a study of Prelude SkinPrep System, a product claimed to enhance the effects of nonprescription 4 percent lidocaine cream for faster-acting local dermal anesthesia. Echo expects to submit a 501(k) premarket notification for the device - intended for use with diabetic patients - to FDA in the near future. "Regulatory clearance would result in a $750,000 milestone payment from our partner, Ferndale Pharma Group Inc., as well as the initiation of royalty revenues from the sale of the product," said CEO Patrick Mooney. In May 2009, Echo granted Ferndale the right to develop, market and sell Prelude in North America and the U.K
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.